Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohamed Moussaoui has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Rachid Daoud

    College of Chemical Sciences and Engineering (CCSE), Chemical and Biochemical Sciences (CBS), Mohammed VI Polytechnic University (UM6P), Benguerir, Morocco

    5 shared publications
  • Soukayna Baammi

    College of Chemical Sciences and Engineering (CCSE) Chemical and Biochemical Sciences (CBS) , Mohammed VI Polytechnic University (UM6P) , 43150, Benguerir, Morocco

    5 shared publications
  • Mouna Baassi

    Laboratory of Physical Chemistry of Materials, Faculty of Sciences Ben M’Sick, Hassan II University of Casablanca, Casablanca 20670, Morocco

    4 shared publications
  • Hatim Soufi

    Laboratory of Physical Chemistry of Materials, Faculty of Sciences Ben M’Sick, Hassan II University of Casablanca, Casablanca 20670, Morocco

    3 shared publications
  • Mohammed Salah

    Team of Chemoinformatics Research and Spectroscopy and Quantum Chemistry, Department of Chemistry, Faculty of Science, University Chouaib Doukkali, B. P. 20, El Jadida 2300, Morocco

    3 shared publications
  • Said Belaaouad

    Laboratory of Physical Chemistry of Materials, Faculty of Sciences Ben M’Sick, Hassan II University of Casablanca, Casablanca 20670, Morocco

    3 shared publications

Latest Publications

  • Open Access

    Computational study of the mechanism and selectivity of [3 + 2] cycloaddition reactions between nitrone and carbodiimide leading to the formation of anticancer 1,2,4-oxadiazolidine compounds from a MEDT perspective

    by Moulay Driss Mellaoui, Mohamed Moussaoui, Soukayna Baammi, Aaziz Jmiai, Rachid Benhida, Souad El Issami, Hanane Zejli, Rachid Daoud

    This study explores the reactivity and pharmaceutical potential of a novel anticancer compound, 1,2,4-oxadiazolidine, synthesized through the [3 + 2] cycloaddition (32CA) reaction between nitrone (1a) and carbodiimide (2a). The mechanism, investigated using Density Functional Theory (DFT) with the B3LYP-D3 functional and the 6-311 + + G(2d,2p) basis set, reveals a polar, regioselective process involving two transition states (TS1 and TS2), with a thermodynamic preference for the ortho isomer, consistent with experimental findings. Molecular docking studies with the EGFR protein (PDB: 4HJO) indicate that compound P1 binds with a higher affinity (-8.8 kcal/mol) compared to the reference drug Erlotinib. Furthermore, molecular dynamics (MD) simulations over 100 ns demonstrate that the P1-EGFR complex exhibits greater stability and lower fluctuation, further supporting its promising interactions with the target protein. In silico ADMET analysis reveals excellent oral absorption, low toxicity, and a favorable pharmacokinetic profile. These findings comprehensively validate P1’s reactivity, affinity, and stability, positioning it as a promising anticancer drug candidate.

  • Open Access

    In Silico Development of Novel Quinazoline-Based EGFR Inhibitors via 3D-QSAR, Docking, ADMET, and Molecular Dynamics

    by Mohamed Moussaoui, Soukayna Baammi, Mouna Baassi, Said Kerraj, Hatim Soufi, Younes Rachdi, Mohammed El Idrissi, Mohammed Salah, Mohammed Elalaoui Belghiti, Rachid Daoud, et al.

    A library of thirty-one quinazoline derivatives was assessed as potential inhibitors of epidermal growth factor receptor kinase (EGFR) using 3D-QSAR methods, namely Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). Training and test sets were generated by aligning the molecules to the lowest-energy conformer of the most active compound. The optimized models exhibited strong statistical performance, with R2 values of 0.981 (CoMFA) and 0.978 (CoMSIA), and cross-validation coefficients (Q2) of 0.645 and 0.729, respectively. External validation confirmed their predictive power, yielding R2 values of 0.929 and 0.909. Guided by these models, eighteen new quinazoline candidates were designed and evaluated for drug likeness and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties using in silico approaches. Molecular docking and molecular dynamics simulations highlighted the binding features and stability of these derivatives, with compound Pred65 demonstrating superior affinity and stability compared to Erlotinib. Collectively, the study provides valuable insights for the optimization of quinazoline scaffolds as EGFR inhibitors, supporting the development of promising anticancer leads.


  • Open Access

    Structure-Guided Design of Novel Diarylpyrimidine-Based NNRTIs Through a Comprehensive In Silico Approach: 3D-QSAR, ADMET Evaluation, Molecular Docking, and Molecular Dynamics

    by Mouna Baassi, Mohamed Moussaoui, Sanchaita Rajkhowa, Hatim Soufi, Rachid Daoud, Said Belaaouad

    Background/Objectives: The emergence of drug-resistant HIV-1 strains challenges the long-term efficacy of current antiretroviral therapies. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are critical in HIV-1 treatment; however, the need for new candidates with improved resistance profiles and pharmacokinetics remains. This study aims to design and evaluate novel NNRTIs targeting both wild-type (WT) and mutant-type (MT) HIV-1 reverse transcriptase (RT) using integrated computational strategies. Methods: We conducted a 3D-QSAR study on 33 naphthyl-diarylpyrimidine derivatives using CoMFA and CoMSIA models. We designed thirty-five novel molecules based on contour map insights. We applied ADMET and drug-likeness filters to prioritize ten candidates. Molecular docking was performed on WT (PDB: 3HVT) and MT (PDB: 4PUO) RT structures. The top candidates underwent 100 ns molecular dynamics (MD) simulations. We analyzed structural stability via RMSD, RMSF, and Rg, while we used SASA and MolSA to assess solvent exposure and surface compactness. Results: The CoMFA and CoMSIA models demonstrated robust predictivity (R2 = 0.979/0.920, Q2 = 0.643/0.546, R2test = 0.747/0.603). P14 and P43 showed higher binding affinities than nevirapine and favorable ADMET profiles. MD simulations confirmed stable binding in WT-RT and adaptive flexibility in MT-RT. SASA and MolSA analysis revealed favorable conformational compaction. Drug-likeness profiles indicated optimal log P, strong hydrogen bonding, and acceptable bioavailability. Conclusions: P14 and P43 demonstrate strong potential as NNRTI leads, combining binding affinity, structural stability, and favorable pharmacokinetics, supporting further experimental development.


  • Open Access

    Multitarget inhibition of CDK2, EGFR, and tubulin by phenylindole derivatives: Insights from 3D-QSAR, molecular docking, and dynamics for cancer therapy

    by Khadijah M. Al-Zaydi, Soukayna Baammi, Mohamed Moussaoui

    Cancer remains one of the leading causes of death globally, presenting significant challenges to healthcare systems due to its complexity and the limitations of current therapeutic strategies. Despite advancements in anticancer drug development, monotherapies often fail to provide long-term efficacy due to the emergence of drug resistance. This resistance is primarily due to the activation of compensatory pathways in cancer cells, which allows them to bypass the effects of single-target therapies. To overcome this, targeting multiple key proteins simultaneously has emerged as a promising strategy to enhance therapeutic outcomes and address resistance mechanisms. In this study, 2-Phenylindole derivatives were explored as MCF7 breast cancer cell line inhibitors using 3D-QSAR modeling to design more effective compounds. The CoMSIA/ SEHDA model demonstrated high reliability (R² = 0.967) and a strong Leave-One-Out cross-validation coefficient (Q² = 0.814), further validated by external testing (R²Pred = 0.722). Six new compounds with potent inhibitory activity were designed, and their favorable ADMET profiles were confirmed. Molecular docking studies revealed that the newly designed compounds exhibited better binding affinities (−7.2 to −9.8 kcal/mol) to key cancer-related targets (CDK2, EGFR, and Tubulin) compared to the reference drug and the most active molecule (molecule 39) in the dataset. Additionally, 100 ns molecular dynamics simulations confirmed the stability of the best-docked complexes, highlighting their potential as promising candidates for anticancer drug development.


  • Open Access

    Design and Optimization of Quinazoline Derivatives as Potent EGFR Inhibitors for Lung Cancer Treatment: A Comprehensive QSAR, ADMET, and Molecular Modeling Investigation

    by Mohamed Moussaoui, Soukayna Baammi, Hatim Soufi, Mouna Baassi, Mohammed Salah, Achraf EL Allali, Belghiti Elalaoui Mohammed, Rachid Daoud, Said Belaaouad

    The epidermal growth factor receptor (EGFR) is part of a protein family that controls cell growth and development. Due to its importance, EGFR has been identified as a suitable target for creating novel drugs. For this research, we conducted a 2D-QSAR analysis on a set of 31 molecules derived from quinazoline, which exhibited inhibitory activity against human lung cancer. This investigation incorporated principal component analysis (PCA) and multiple linear regression (MLR), leading to the development of QSAR models with strong predictive capabilities (R 2 = 0.745, R 2_adj = 0.723, MSE = 0.061, R 2_test = 0.941, and Q 2_cv = 0.669). The reliability of these models was confirmed through internal, external, Y-randomization, and applicability domain validations. Leveraging the predictions from the QSAR model, we designed 18 new molecules based on the modifications at the N-3 and C-6 positions of the quinazoline ring, with electronegative substituents at these positions fostering optimal polar interactions and hydrophobic contacts within the ATP-binding site of EGFR, significantly enhancing the inhibitory activity against the lung cancer cell line. Subsequently, ADMET predictions were conducted for these 18 compounds, revealing outstanding ADMET profiles. Molecular docking analyses were performed to investigate the interactions between the newly designed molecules-Pred15, Pred17, Pred20, Pred21-and the EGFR protein, indicating high affinity of these proposed compounds to EGFR. Furthermore, molecular dynamics (MD) simulations were utilized to assess the stability and binding modes of compounds Pred17, Pred20, and Pred21, reinforcing their potential as novel inhibitors against human lung cancer. Overall, our findings suggest that these investigated compounds can serve as effective inhibitors, showcasing the utility of our analytical and design approach in the identification of promising therapeutic agents.


  • Open Access

    QSAR, ADMET, molecular docking, and dynamics studies of 1,2,4-triazine-3(2H)-one derivatives as tubulin inhibitors for breast cancer therapy

    by Mohamed Moussaoui, Soukayna Baammi, Hatim Soufi, Mouna Baassi, Achraf El Allali, M. E. Belghiti, Rachid Daoud, Said Belaaouad

    Breast cancer remains a leading cause of cancer-related deaths among women globally, necessitating the development of more effective therapeutic agents with minimal side effects. This study explores novel 1,2,4-triazine-3(2H)-one derivatives as potential inhibitors of Tubulin, a pivotal protein in cancer cell division, highlighting a targeted approach in cancer therapy. Using an integrated computational approach, we combined quantitative structure–activity relationship (QSAR) modeling, ADMET profiling, molecular docking, and molecular dynamics simulations to evaluate and predict the efficacy and stability of these compounds. Our QSAR models, developed through rigorous statistical analysis, revealed that descriptors such as absolute electronegativity and water solubility significantly influence inhibitory activity, achieving a predictive accuracy (R2) of 0.849. Molecular docking studies identified compounds with high binding affinities, particularly Pred28, which exhibited the best docking score of − 9.6 kcal/mol. Molecular dynamics simulations conducted over 100 ns provided further insights into the stability of these interactions. Pred28 demonstrated notable stability, with the lowest root mean square deviation (RMSD) of 0.29 nm and root mean square fluctuation (RMSF) values indicative of a tightly bound conformation to Tubulin. The novelty of this work lies in its methodological rigor and the integration of multiple advanced computational techniques to pinpoint compounds with promising therapeutic potential. Our findings advance the current understanding of Tubulin inhibitors and open avenues for the synthesis and experimental validation of these compounds, aiming to offer new solutions for breast cancer treatment.


  • Multi-combined QSAR, molecular docking, molecular dynamics simulation, and ADMET of Flavonoid derivatives as potent cholinesterase inhibitors

    by Hatim Soufi, Mohamed Moussaoui, Soukayna Baammi, Mouna Baassi, Mohammed Salah, Rachid Daoud, Achraf El Allali, M. E. Belghiti, Mohammed Moutaabbid, Said Belaaouad

    In searching for a new and efficient therapeutic agent against Alzheimer's disease, a Quantitative structure-activity relationship (QSAR) was derived for 45 Flavonoid derivatives recently synthesized and evaluated as cholinesterase inhibitors. The multiple linear regression method (MLR) was adopted to develop an adequate mathematical model that describes the relationship between a variety of molecular descriptors of the studied compounds and their biological activities (cholinesterase inhibitors). Golbraikh and Tropsha criteria were applied to verify the validity of the built model. The built MLR model was statistically reliable, robust, and predictive (R2 = 0.801, Q2cv = 0.876, R2test = 0.824). Dreiding energy and Molar Refractivity were the major factors that govern the Anti-cholinesterase activity. These results were further exploited to design a new series of Flavonoid derivatives with higher Anti-cholinesterase activities than the existing ones. Thereafter, molecular docking and molecular dynamic studies were performed to predict the binding types of the designed compounds and to investigate their stability at the active site of the Butyrylcholinestérase BuChE protein. The negative and low binding affinity calculated for all designed compounds shows that designed compound 1 has a favorable affinity for the 4TPK. Moreover, molecular dynamics simulation studies confirmed the stability of designed compound 1 in the active pocket of 4TPK over 100 ns. Finally, the ADMET analysis was incorporated to analyze the pharmacokinetics and toxicity parameters. The designed compounds were found to meet the ADMET descriptor criteria at an acceptable level having respectable intestinal permeability and water solubility and can reach the intended destinations.Communicated by Ramaswamy H. Sarma.


  • In silico design of novel CDK2 inhibitors through QSAR, ADMET, molecular docking and molecular dynamics simulation studies

    by Mohamed Moussaoui, Mouna Baassi, Soukayna Baammi, Hatim Soufi, Mohammed Salah, Rachid Daoud, Achraf EL Allali, M.E. Belghiti, Said Belaaouad

    The present study aims to investigate about the quantitative structure-activity relationship (QSAR) of a series of Thiazole derivatives reported as anticancer agents (hepatocellular carcinoma), using principally the electronic descriptors calculated by the DFT method and by applying the multiple linear regression method. The developed model showed good statistical parameters (R2 = 0.725, R2adj = 0.653, MSE = 0.060, R2test = 0.827, Q2cv = 0.536). The energy EHOMO orbital, electronic energy (TE), shape coefficient (I), number of rotatable bonds (NROT), and index of refraction (n) were revealed to be the main descriptors influencing the anti-cancer activity. Further, new Thiazole derivatives have been designed and their activities and pharmacokinetic properties have been predicted using the validated QSAR model. The designed molecules were then assessed to molecular docking (MD), and molecular dynamic (MDs) simulation accompanied by the calculation of the binding affinity using MMPBSA script according to 100 ns a simulation trajectory, to study both their affinity and their stability towards CDK2 as a target protein for the cancer disease treatment. This research concluded with the identification of four new CDK2 inhibitors which are A1, A3, A5, and A6 showing good pharmacokinetic properties. The MDs results revealed that the newly designed compound A5 remained stable in the active center of the discovered CDK2 protein, indicating its potential as a novel inhibitor for the treatment of hepatocellular carcinoma. The current findings may eventually contribute to the development of robust CDK2 inhibitors in the future.Communicated by Ramaswamy H. Sarma.